` MRVI (Maravai LifeSciences Holdings Inc) vs S&P 500 Comparison - Alpha Spread

MRVI
vs
S&P 500

Over the past 12 months, MRVI has underperformed S&P 500, delivering a return of -41% compared to the S&P 500's +14% growth.

Stocks Performance
MRVI vs S&P 500

Loading
MRVI
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MRVI vs S&P 500

Performance Gap Between MRVI and GSPC
HIDDEN
Show

Performance By Year
MRVI vs S&P 500

Loading
MRVI
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Maravai LifeSciences Holdings Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Maravai LifeSciences Holdings Inc
Glance View

Maravai LifeSciences Holdings Inc. operates in the niche yet burgeoning market of life sciences, where its business revolves around the creation and supply of essential products and services for biotechnology workflows. Founded in 2014 and headquartered in San Diego, California, Maravai specializes in providing key components for the development of diagnostics and therapeutics. A significant portion of its revenue is driven by its business unit, TriLink BioTechnologies, which is instrumental in the synthesis of nucleic acids, notably mRNA and modified nucleotides – critical for the development of mRNA vaccines like those used in combating COVID-19. This has positioned Maravai as a crucial player during the pandemic, spotlighting its capability to provide high-quality inputs that support leading-edge scientific innovations. The company’s financial engine is powered by its diversified product offerings across three main segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. Beyond just supplying raw materials, Maravai elevates its contributions by ensuring these components meet rigorous quality standards necessary for clinical applications. The robust demand for both biopharmaceutical innovation and bioprotection has allowed Maravai to capitalize on trends such as personalized medicine and gene therapy. By navigating these influential currents in the biotechnology space, Maravai LifeSciences not only gains from direct sales of its products but also cultivates long-standing partnerships across pharmaceutical and research organizations, underscoring its integral role in the ongoing evolution of life sciences.

MRVI Intrinsic Value
HIDDEN
Show
Back to Top